Latest Content

10 of 498 Shown
  • How I Manage HCC Risk Following HCV Cure

    Paul Y. Kwo MD - 2/14/2018
    Which patients, who have achieved a sustained virologic response with HCV treatment, need to be screened for hepatocellular carcinoma? Here’s my approach.
  • Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

    Listen to downloadable audio from a series of live Webinars by Ira M. Jacobson, MD, and Paul Y. Kwo, MD, in which the optimal management of patients with HCV who have achieved SVR is discussed and audience questions are answered.
    Date Posted: 2/14/2018
  • Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

    In this downloadable slideset, Ira M. Jacobson, MD, and Paul Y. Kwo, MD, review optimal management of patients with HCV who have achieved SVR, including recommendations for HCV RNA and HCC monitoring.
    Date Posted: 2/6/2018
  • Hepatitis C Update: A Growing Challenge With Evolving Management Solutions

    In this updated slideset for primary care clinicians, hepatitis expert Terry D. Box, MD, reviews the changing epidemiology of hepatitis C infections, age- and risk-based HCV screening, follow-up after testing in the primary care and specialist settings, and counseling patients on the benefits of HCV screening and treatment.
    Date Posted: 2/2/2018
  • Adopting Strategies to Eliminate HCV in Persons Who Inject Drugs

    Frederick L. Altice MD - 1/19/2018
    Eliminating HCV infection among persons who inject drugs is a daunting task whether tackling it from a patient care perspective, through practice transformation, or by influencing policies that improve access to treatment. Nonetheless, there are practical steps that can be taken by clinicians to improve the HCV continuum of care for this challenging population. Here’s my take on some of those steps.
  • Interactive Virtual Presentation cme-icon

    Hepatitis C Update: A Growing Challenge With Evolving Management Solutions

    In this updated CME-certified interactive presentation targeted to primary care clinicians, hepatitis expert Terry D. Box, MD, reviews the changing epidemiology of hepatitis C infections, age- and risk-based HCV screening, follow-up after testing in the primary care and specialist settings, and counseling patients on the benefits of HCV screening and treatment.
    Faculty: Terry D. Box MD, Brian L. Pearlman MD, FACP, FAASLD, Mary Speigle NP
    Released: 1/17/2018
  • How New Data From AASLD 2017 Inform the Use of 8-Week Regimens for HCV

    Ira M. Jacobson MD - 1/9/2018
    How will data presented at AASLD 2017 on 8-week therapy have an impact on management of patients with HCV infection? Here’s my take.
  • New Insights on NAFLD/NASH From AASLD 2017

    Philip Newsome PhD, FRCPE - 1/8/2018 3 comments / Last Comment: 2/13/2018
    Here’s my take on how new data from AASLD 2017 on noninvasive imaging modalities and emerging investigational agents may affect the NAFLD/NASH patient management landscape.
  • How Injection Drug Use Affects HCV Treatment

    Norah Terrault MD, MPH - 1/3/2018 1 comment / Last Comment: 1/16/2018
    Here’s my take on why colocalization of HCV treatment with other medical and social services may be ideal for persons who inject drugs.
  • Hepatitis Alert: HCV Elimination—Closing the Gaps in Screening, Care Linkage, and Treatment

    Listen to downloadable audio from a series of live Webinars in which expert faculty review important strategies for closing gaps along the HCV care continuum with a focus on overcoming barriers to reach and treat persons who inject drugs.
    Date Posted: 1/2/2018
10 of 498 Shown
Show 10 More
Loading...  
Decision Support
Free
inPractice
Immediate answers to treatment questions
More than just up to date